Details for Patent: 11,807,629
Which drugs does patent 11,807,629 protect, and when does it expire?
Patent 11,807,629 protects XPOVIO and is included in one NDA.
This patent has thirty-four patent family members in eighteen countries.
Summary for Patent: 11,807,629
| Title: | Polymorphs of Selinexor |
| Abstract: | The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms. |
| Inventor(s): | Brian C. Austad, David G. Roe |
| Assignee: | Karyopharm Therapeutics Inc |
| Application Number: | US17/365,656 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 11,807,629
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-005 | Mar 10, 2025 | RX | Yes | No | 11,807,629 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 11,807,629 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,807,629 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,807,629
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015301484 | ⤷ Start Trial | |||
| Australia | 2020203246 | ⤷ Start Trial | |||
| Australia | 2021286266 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
